Welcome to LookChem.com Sign In|Join Free
  • or
1-[(4-dimethylaminophenyl)carbonyl]piperazine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

610802-19-2

Post Buying Request

610802-19-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

610802-19-2 Usage

Class

Piperazine

Psychoactive

Yes

Effects

Stimulating, euphoric, hallucinogenic (altered perception, visual and auditory hallucinations, dissociative effects)

Legal Status

Illegal in many countries due to potential for abuse and harm

Use

Ingredient in "party pills" and "legal highs"

Long-term Effects

Not well understood

Health Risks

Not well understood

Approved for Human Consumption

No

Check Digit Verification of cas no

The CAS Registry Mumber 610802-19-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,1,0,8,0 and 2 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 610802-19:
(8*6)+(7*1)+(6*0)+(5*8)+(4*0)+(3*2)+(2*1)+(1*9)=112
112 % 10 = 2
So 610802-19-2 is a valid CAS Registry Number.

610802-19-2Downstream Products

610802-19-2Relevant academic research and scientific papers

Discovery of novel Bcr-AblT315I inhibitors with flexible linker. Part 1: Confirmation optimization of phenyl-1H-indazol-3-amine as hinge binding moiety

Pan, Xiaoyan,Liang, Liyuan,Sun, Ying,Si, Ru,Zhang, Qingqing,Wang, Jin,Fu, Jia,Zhang, Junjie,Zhang, Jie

, p. 232 - 242 (2019)

As a continuation to our research, a series of novel Bcr-Abl inhibitors incorporated with 6-phenyl-1H-indazol-3-amine as hinge binding moiety (HBM) were developed based on confirmation analysis. Biological results indicated that these compounds exhibited an enhanced inhibition against Bcr-AblWT and Bcr-AblT315I in kinases assays, along with improved anti-proliferative activities in K562 cell assays. In particular, compound Y9 displayed comparable potency with that of imatinib. It potently inhibited Bcr-AblWT and Bcr-AblT315I kinases with IC50 of 0.043 μM and 0.17 μM, respectively. Furthermore, compound Y9 inhibited the proliferation of K562 and K562R cells with IC50 of 1.65 μM and 5.42 μM, respectively. Therefore, 6-phenyl-1H-indazol-3amine as HBM, combined with flexible linker, is a successful strategy contribute to research on T315I mutant resistance, and compound Y9 could be served as a starting point for further optimization.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 610802-19-2